NCT01689285已完成1 期
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of VZV and HSV Infections in Children, Phase I (VALID-I)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Geometric Mean Ratios and 90% confidence intervals of pharmacokinetic parameters of acyclovir taken as valacyclovir tablet or oral solution
研究概览
简要总结
A new paediatric formulation (oral liquid) has been developed for flexible and accurate dosing of valacyclovir in children. To establish the bioavailability of this new formulation, healthy volunteers will be exposed to the new formulation and to valacyclovir tablets. The concentration of valacyclovir in their blood after exposure to the oral liquid will be measured and compared to the tablet.
详细描述
Bioequivalence of the new valcyclovir formulation will be tested according to the EMA guideline for bioequivalence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is at least 18 and not older than 55 years of age at screening.
- •Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to the first dosing
- •Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.
- •Subject has signed the Informed Consent Form prior to screening evaluations.
- •Subject is in good age-appropriate health condition as established by medical history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to the first dose. Results of biochemistry, haematology and urinalysis testing should be within the laboratory's reference ranges (see Appendix A). If laboratory results are not within the reference ranges, the subject is included on condition that the investigator judges that the deviations are not clinically relevant. This should be clearly recorded.
- •Subject has a normal blood pressure and pulse rate, according to the investigator's judgement.
- •Female subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or is of childbearing potential with adequate contraception (e.g. hysterectomy, bilateral tubal ligation, (nonhormonal) intrauterine device, total abstinence, double barrier methods, vasectomized partner).
排除标准
- •Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
- •Positive HIV, hepatitis B or C test.
- •Therapy with any drug (for two weeks preceding dosing), except for acetaminophen.
- •Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular disorders, neurological disorders (especially seizures and migraine), gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders (especially diabetes mellitus), coagulation disorders.
- •Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
- •History of or current abuse of drugs, alcohol or solvents.
- •Inability to understand the nature and extent of the trial and the procedures required.
- •Participation in a drug trial within 60 days prior to the first dose.
- •Donation of blood within 60 days prior to the first dose.
- •Febrile illness within 3 days before the first dose.
- •Pregnant female (as confirmed by an HCG test performed less than 4 weeks before the first dose) or breast-feeding female.
研究组 & 干预措施
valacyclovir tablet
Active Comparator
Administration of 500 mg once daily on day 1 (group A) or on day 8 (group B)
干预措施: valacyclovir tablet (Drug)
valacyclovir oral solution
Experimental
Administration of 500 mg once daily on day 1 (group B) or on day 8 (group A)
干预措施: valacyclovir oral solution (Drug)
结局指标
主要结局
Geometric Mean Ratios and 90% confidence intervals of pharmacokinetic parameters of acyclovir taken as valacyclovir tablet or oral solution
时间窗: up to 8 days
bioequivalence will be determined by comparing AUC0-inf, Cmax and tmax of both formulations in healthy adult volunteers.
次要结局
- Determine the safety profile of a single dose of valacyclovir oral solution(day 1 and 8)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum MalariaMalaria,FalciparumNCT01992900sigma-tau i.f.r. S.p.A.300
已完成
不适用
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial EpilepsyInfantile SpasmsNCT02220114Orphelia Pharma38
已完成
不适用
Acceptability study of a new paediatric formulation of Orphacol® (cholic acid) in paediatric patients treated for inborn errors in primary bile acid synthesis due to 3ß-Hydroxy-?5-C27- steroid oxidoreductase deficiency or ?4-3-Oxosteroid-5ß-reductase deficiency.K76.8Other specified diseases of liverDRKS00013645aboratoires CTRS4
招募中
不适用
Palatability testing of a new paediatric formulation of valacyclovir for the prophylaxis and treatment of VZV and HSV infections in children - VALID 0chickenpoxherpes10047438NL-OMON43617niversitair Medisch Centrum60
进行中（未招募）
1 期
Palatability testing of a new paediatric formulation of valacyclovirHerpes virus infections, especially Herpes Simplex, Varicella Zoster and CytomegalovirusMedDRA version: 14.1Level: PTClassification code 10019973Term: Herpes virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-000577-22-NLRadboud University Nijmegen Medical Centre64